2ZU4 image
Deposition Date 2008-10-12
Release Date 2009-01-13
Last Version Date 2024-11-20
Entry Detail
PDB ID:
2ZU4
Title:
Complex structure of SARS-CoV 3CL protease with TG-0204998
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.93 Å
R-Value Free:
0.26
R-Value Work:
0.23
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:3C-like proteinase
Chain IDs:A
Chain Length:306
Number of Molecules:1
Biological Source:SARS coronavirus
Ligand Molecules
Peptide-like Molecules
PRD_000568
Primary Citation
Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds
J.Biol.Chem. 284 7646 7655 (2009)
PMID: 19144641 DOI: 10.1074/jbc.M807947200

Abstact

Human coxsackievirus (CV) belongs to the picornavirus family, which consists of over 200 medically relevant viruses. In picornavirus, a chymotrypsin-like protease (3C(pro)) is required for viral replication by processing the polyproteins, and thus it is regarded as an antiviral drug target. A 3C-like protease (3CL(pro)) also exists in human coronaviruses (CoV) such as 229E and the one causing severe acute respiratory syndrome (SARS). To combat SARS, we previously had developed peptidomimetic and zinc-coordinating inhibitors of 3CL(pro). As shown in the present study, some of these compounds were also found to be active against 3C(pro) of CV strain B3 (CVB3). Several crystal structures of 3C(pro) from CVB3 and 3CL(pro) from CoV-229E and SARS-CoV in complex with the inhibitors were solved. The zinc-coordinating inhibitor is tetrahedrally coordinated to the His(40)-Cys(147) catalytic dyad of CVB3 3C(pro). The presence of specific binding pockets for the residues of peptidomimetic inhibitors explains the binding specificity. Our results provide a structural basis for inhibitor optimization and development of potential drugs for antiviral therapies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures